Kezar Life Sciences, Inc. (NASDAQ:KZR) Stake Trimmed by Stonepine Capital Management LLC

Stonepine Capital Management LLC lowered its stake in Kezar Life Sciences, Inc. (NASDAQ:KZR) by 92.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 110,000 shares of the company’s stock after selling 1,381,305 shares during the quarter. Stonepine Capital Management LLC owned approximately 1.51% of Kezar Life Sciences worth $739,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of KZR. JPMorgan Chase & Co. increased its stake in Kezar Life Sciences by 613.8% in the 4th quarter. JPMorgan Chase & Co. now owns 11,884 shares of the company’s stock worth $80,000 after purchasing an additional 10,219 shares in the last quarter. Dimensional Fund Advisors LP purchased a new position in Kezar Life Sciences in the 4th quarter worth about $217,000. BML Capital Management LLC acquired a new stake in Kezar Life Sciences during the 4th quarter worth about $327,000. Shay Capital LLC acquired a new stake in Kezar Life Sciences during the 4th quarter worth about $398,000. Finally, Peapod Lane Capital LLC acquired a new stake in Kezar Life Sciences during the 4th quarter worth about $833,000. Hedge funds and other institutional investors own 67.90% of the company’s stock.

Analysts Set New Price Targets

Separately, William Blair restated an “outperform” rating on shares of Kezar Life Sciences in a research report on Friday, February 28th.

Kezar Life Sciences Trading Up 0.2%

Shares of NASDAQ KZR opened at $4.07 on Friday. Kezar Life Sciences, Inc. has a one year low of $3.62 and a one year high of $9.18. The firm has a market capitalization of $29.74 million, a PE ratio of -0.31 and a beta of 0.61. The company has a current ratio of 7.65, a quick ratio of 7.65 and a debt-to-equity ratio of 0.05. The business has a 50-day moving average price of $4.64 and a two-hundred day moving average price of $5.94.

Kezar Life Sciences (NASDAQ:KZR) last announced its quarterly earnings data on Tuesday, May 13th. The company reported ($2.27) EPS for the quarter, topping analysts’ consensus estimates of ($2.56) by $0.29. As a group, analysts predict that Kezar Life Sciences, Inc. will post -4.39 earnings per share for the current fiscal year.

About Kezar Life Sciences

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.